Diligence memo · auto-generated · as of July 2, 2026
Kriya Therapeutics, Inc.
Kriya Therapeutics, Inc. looks over-valued against its niche peers and is active on financing cadence.
Businessfiled
Kriya Therapeutics, Inc. operates in Biotechnology, based in MORRISVILLE. Kriya is a biopharmaceutical company developing gene therapy to address common diseases that impact millions of people worldwide. Learn more.
Sub-sector tags: biotech, pharma.
Capital & rounds (filed)filed
Kriya Therapeutics, Inc. has raised $870M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series D+ (a $100M–$400M round).
Largest single filing: $362M on 2022-05-10.
Most recent recorded round closed around 2025-07-31.
Valuation (modeled)modeled
Provath models Kriya Therapeutics, Inc. at approximately $2.5B (range $1.5B–$3.0B). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 2.79× the median modeled value of Series D+ Biotechnology companies in 2025–2027 (33 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 10 months.
Last raise 11 mo ago; this sector typically re-raises about every 14 months.
Raising on or ahead of the sector's normal rhythm.
The last round was 1.0× smaller than the prior — a bridge or down round.
Comparablesmixed
Capital scale ranks ahead of 100% of Biotechnology peers (4293 compared).
Modeled value ranks above 96% of those peers.
Closest niche peers: Pathos AI, Inc., Sensei Biotherapeutics, Inc., Odyssey Therapeutics, Inc., Rhodenergy An Environmental Co Corp, Tectonic Therapeutic, Inc..
Peoplefiled
20 named people on file across officers, directors and signatories.
Risks & flagsmixed
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.